Notice of AGM
Updated : 12:01
14 March 2019 12:00 GMT
Notice of Annual General Meeting
AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2019 and Shareholders' Circular (the Notice).
The Notice has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm. The Notice is also available on the Company's website at www.astrazeneca.com/agm.
The Company's Annual Report and Form 20-F Information 2018 was published on 5 March 2019.
The Notice is being despatched to shareholders today.
The meeting place for the Annual General Meeting (AGM) will be The Landmark London Hotel, 222 Marylebone Road, London NW1 6JQ and the AGM will commence at 2.30 pm (BST) on 26 April 2019.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations | ||
Gonzalo Viña | UK/Global | +44 203 749 5916 |
Rob Skelding | UK/Global | +44 203 749 5821 |
Matt Kent | UK/Global | +44 203 749 5906 |
Jennifer Hursit | UK/Global | +44 203 749 5762 |
Christina Malmberg Hägerstrand | Sweden | +46 8 552 53 106 |
Michele Meixell | US | +1 302 885 2677 |
Investor Relations | ||
Thomas Kudsk Larsen | +44 203 749 5712 | |
Henry Wheeler | Oncology | +44 203 749 5797 |
Christer Gruvris | BioPharma - Cardiovascular; Metabolism | +44 203 749 5711 |
Nick Stone | BioPharma - Respiratory; Renal | +44 203 749 5716 |
Josie Afolabi | Other | +44 203 749 5631 |
Craig Marks | Finance; Fixed Income | +44 7881 615 764 |
Jennifer Kretzmann | Retail Investors; Corporate Access | +44 203 749 5824 |
US toll-free | +1 866 381 72 77 |
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.